Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory MyelofibrosisGlobeNewsWire • 10/28/26
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire • 10/21/26
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/19/26
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERNBusiness Wire • 10/12/26
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption ExpandsMarketBeat • 09/16/26
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use ExpandsMarketBeat • 09/13/26
Geron Corp: Management's Plan Taking Shape As Competition Heats Up In MyelofibrosisSeeking Alpha • 08/18/26
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/05/26
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026GlobeNewsWire • 07/22/26
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive ChairmanGlobeNewsWire • 07/15/26
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/14/26
Geron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-UpSeeking Alpha • 07/01/26
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)Zacks Investment Research • 06/04/26
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewsWire • 06/01/26